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Abstract
Background: Point-of-care testing (POCT) of prothrombin
time, expressed as International Normalized Ratio (INR), is
widely used to monitor patients in oral anticoagulation treat-
ment. Guidelines recommend that POCT users should par-
ticipate in an external quality assessment (EQA) scheme
whenever available. The aim of this study was to investigate
which European countries provide EQA for POCT INR and
to compare how these schemes are organized.
Methods: Thirty European countries were invited to partic-
ipate in this study. Those who reported that they provide
EQA for POCT INR filled in a questionnaire dealing with
different aspects of their schemes.
Results: Nineteen countries reported that they do not provide
EQA for POCT INR, while 12 organizations from nine coun-
tries reported that they provide this service. Most of these
countries circulate lyophilized samples with for the partici-
pants unknown target values. Samples with certified INR
values and procedures using split samples with fresh patient
samples are also used. The acceptability limits vary from
15% to 30%, and the total number of samples circulated per
year varies from 1 to 12. Most of the countries organize
educational activities together with their schemes.
Conclusions: This study demonstrates that there is a wide
variation in the way EQA for POCT INR is performed in
Europe and that there are many European countries that do
not provide this service. Even though our findings indicate
that EQA for POCT INR draws some challenges, especially
in providing suitable control materials, participation in such
schemes is considered useful.
*Corresponding author: Anne Stavelin, NOKLUS, Box 6165,
N-5892 Bergen, Norway
Phone: q47 55 97 95 00, Fax: q47 55 97 95 10,
E-mail: anne.stavelin@noklus.no
Received June 4, 2011; accepted September 2, 2011;
previously published online September 26, 2011
Keywords: anticoagulation treatment; external quality
assessment; international normalized ratio; point-of-care
testing.
Introduction
Point-of-care testing (POCT) of prothrombin time, expressed
as International Normalized Ratio (INR), is widely used to
monitor patients in oral anticoagulation treatment with
vitamin K antagonists (e.g., warfarin, acenocoumarol, phen-
procoumon). There are several POCT INR devices in use
today, and it is important that the devices give reliable and
valid results. Good measurement quality is essential for safe
and efficacious treatment (1), and efforts have been made to
improve harmonization of INR results (2). POCT is per-
formed in several locations, such as hospital clinics, throm-
bosis clinics, general practitioners offices, nursing homes and
in pharmacies (3).
Several guidelines recommend that POCT users should
participate in an external quality assessment scheme (EQAS)
(1, 4–6). The Clinical and Laboratory Standards Institute
(CLSI) (5) which has a focus on the hospital-based POCT
programs in general, states that EQAS plays an important
role in the POCT quality management in reducing errors. In
another CLSI document (6), which deals with POCT and
anticoagulation therapy, it is recommended that POCT INR
users in professional settings should enrol and regularly par-
ticipate in an EQAS whenever available. A recent review on
POCT in hemostasis (1) states that participation in an EQAS
is essential in the overall POCT quality assurance program,
and that there are still relatively few providers of these
schemes.
External quality assessment (EQA) organizations provide
EQAS for many different components, and the focus has
mainly been on hospital laboratories. In recent years, how-
ever, an increasing number of EQA organizers have estab-
lished EQAS for different POCT devices, e.g., for blood
glucose, hemoglobin, cholesterol, coagulation and urine
strips analyses. The purpose of these EQASs is to evaluate
and improve POCT quality in order to ensure safe patient
treatment. Depending on the type of scheme different aspects
can be addressed; the quality of one instrument brand com-
pared to others, the quality of the users instrument and re-
agent lot compared to others, as well as the competence of
the users. Education of the users is considered to be an essen-
tial part of the EQAS (7).
Several studies have shown that participation in an EQAS
for POCT analyses is useful to improve analytical quality;
e.g., for mononucleosis tests and urine dip-slide tests in
Norway (8, 9), for group A streptococcus tests in Finland
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(10) and in Switzerland (11), for hemoglobin tests in Bel-
gium (12) and for blood glucose tests in Germany (13). The
United Kingdom National External Quality Assessment Ser-
vice (UKNEQAS) has reported their experience with EQAS
for POCT INR over a 6-year period, and stated that this kind
of control is both possible and necessary for health care pro-
fessionals to obtain good analytical quality (14).
Publications show that an EQAS for POCT INR is avail-
able in the Czech Republic (15), the Netherlands (16), Nor-
way (17) and the UK (14). To our knowledge, however, no
studies have investigated the coverage of POCT INR
schemes in Europe. The aim of this study is, therefore, to
establish which of the European countries provide an EQAS
for POCT INR, and to compare how these schemes are
organized.
Materials and methods
This study was carried out in cooperation with the European Organi-
zation for External Quality Assurance in Laboratory Medicine
(EQALM) (18). In February 2010, an invitation to participate in this
study was sent all EQALM members as well as non-members in
order to invite as many European countries as possible. A total of
30 of the 44 European countries classified by the United Nations
(19) were contacted. The invited countries were asked if they have
a national organizer that provides an EQAS for POCT INR. Those
EQA organizers that reported that they do provide this service were
asked to fill in a questionnaire of 23 questions dealing with different
aspects of their schemes. The questionnaires were completed in the
period from April to August 2010.
We were not able to contact the following European countries:
Albania, Andorra, Belarus, Bosnia and Herzegovina, Greece, Liech-
tenstein, Macedonia, Malta, Moldova, Monaco, Montenegro, San
Marino, Serbia and Ukraine. We have, however, no reason to believe
that these countries host any EQA organizers of significance for this
study.
Results
Providers of EQAS for POCT INR in Europe
Twenty-eight of 30 countries responded to the invitation.
Twelve EQA organizers from nine European countries
reported that they provide EQAS for POCT INR (Table 1),
and all completed the questionnaire. Nineteen European
countries (Belgium, Bulgaria, Croatia, France, Germany,
Iceland, Ireland, Italy, Latvia, Luxemburg, Poland, Portugal,
Romania, Russia, Slovakia, Slovenia, Spain, Sweden and
Turkey) reported that they did not provide this service.
Different EQAS approaches
Most of the countries offer the traditional EQAS where the
participants receive samples with, for the participants,
unknown target values (Table 1). In the Czech Republic, they
also include a post-analytical phase where the participants
are asked to interpret their INR results, based on a short case
history. In Denmark and one of the Swiss organizations, they
offer a split sample procedure where the POCT users analyze
a fresh patient sample on their device, and send a venous
sample to a ‘‘certified’’ hospital laboratory for comparison
(Table 1). In Austria and the Czech Republic, no control
samples are distributed to the INRatio participants since there
are currently no materials available for these instruments.
The participants receive test strips from one batch and are
simply asked to analyze one arbitrary capillary patient sam-
ple and report the two QC values given by the strip (sec-
onds). In the Netherlands, a set of five lyophilized plasmas
with certified, but for the participant unknown, INR values
are distributed to the participants on request (Table 1).
Number of samples, participants and POCT devices
The total number of samples distributed per year varies
between the EQA organizers from one to 12 with a median
of four (two samples two times a year) (Table 1). The num-
ber of participants varies from 75 to 2665 (Table 2). Den-
mark and Hungary have at present no participants. Almost
all countries distribute control samples to the general prac-
titioners and to hospital clinics that perform POCT INR.
Some nursing homes participate in Norway and in the Qual-
ity Control Center Switzerland (CSCQ), and some pharma-
cies participate in the UK and CSCQ. Only the ECAT
organization provides control samples to patients. All coun-
tries offer an EQAS for the CoaguChek series users, the most
commonly used POCT INR devices (Table 2).
Types of control material
The control materials used for the different POCT INR
devices are shown in Table 3. The majority of EQA organ-
izers reported that they use lyophilized samples, i.e., recon-
stituted lyophilized plasma or lyophilized whole blood. In
addition, a calcium chloride solution is distributed to the
CoaguChek users for activation of the coagulation cascade.
The Wales External Quality Assessment Schemes (WEQAS)
use an artificial liquid material, which is based on bovine
plasma with added stabilizers and dyes to make it look like
whole blood. Calcium chloride activation is not required and
the material is sent frozen. The material exploits the fact that
the Coagucheck XS system measures the thrombin produced
in the sample. The Federation of Netherlands Thrombosis
services (FNT) use fresh frozen pooled patient samples, i.e.,
plasma to the CoaguChek users and whole blood to the
ProTime users. The pooled plasma is stored frozen, thawed
on the day of sample distribution and sent to the participants
together with a calcium chloride solution. Artificial whole
blood samples are prepared by mixing compatible fresh red
blood cells with the pooled patient plasma.
Target value and acceptability limits
In the ‘‘non-traditional’’ EQAS in the Netherlands, a refer-
ence method is used to establish the target value, while
results from a standard laboratory method is used as target
in the split sample procedure in Denmark and one of the
Swiss schemes. The other schemes use consensus values
from the participants, i.e., mean or median of method group
Brought to you by | Universitetsbiblioteket i Bergen (Universitetsbiblioteket i Bergen)
Authenticated | 172.16.1.226
Download Date | 2/10/12 3:16 PM
Stavelin et al.: External quality assessment of POCT INR in Europe 83
Article in press - uncorrected proof
a
bl
e
1
Pr
o
v
id
er
s
o
fE
QA
S
fo
rP
O
CT
IN
R
in
Eu
ro
pe
.T
yp
e
o
fE
QA
S,
n
u
m
be
ro
fs
am
pl
es
an
d
sp
ec
ia
lf
ea
tu
re
s
is
sh
ow
n
fo
re
ac
h
EQ
AS
.
Co
un
try
EQ
A
o
rg
an
iz
er
Tr
ad
iti
on
al
EQ
AS
N
um
be
ro
f
N
um
be
ro
f
To
ta
ln
u
m
be
r
Sp
ec
ia
lf
ea
tu
re
s
sa
m
pl
es
su
rv
ey
s
o
fs
am
pl
es
pe
rs
u
rv
ey
pe
ry
ea
r
pe
ry
ea
r
A
us
tri
a
O¨
QU
AS
TA
A
us
tri
an
So
ci
et
y
o
fQ
ua
lity
A
ss
ur
an
ce
Ye
s
1
4
4
IN
Ra
tio
u
se
rs
re
ce
iv
es
n
o
co
n
tr
o
l
an
d
St
an
da
rd
iz
at
io
n
(N
of
or
IN
Ra
tio
)
sa
m
pl
es
,b
ut
re
po
rts
v
al
ue
s
(se
co
nd
s,
n
o
t
IN
R)
fro
m
th
e
o
n
-b
oa
rd
QC
sy
ste
m
Cz
ec
h
R
ep
ub
lic
SE
K
K
Ex
te
rn
al
qu
al
ity
as
se
ss
m
en
t
sy
ste
m
fo
r
Ye
s
2
2a
4
Po
st
-a
na
ly
tic
al
ph
as
es
ar
e
in
cl
ud
ed
cl
in
ic
al
la
bo
ra
to
rie
s
(N
of
or
IN
Ra
tio
)
(in
ter
pre
ta
tio
n
o
ft
he
IN
R
co
n
tr
o
lr
es
u
lts
ba
se
d
o
n
a
sh
or
tc
as
e
hi
sto
ry
)
IN
Ra
tio
u
se
rs
re
ce
iv
e
n
o
co
n
tr
o
l
sa
m
pl
es
,b
ut
re
po
rts
v
al
ue
s
(se
co
nd
s,
n
o
t
IN
R)
fro
m
th
e
o
n
-b
oa
rd
QC
sy
ste
m
D
en
m
ar
k
D
EK
S
D
an
ish
In
st
itu
te
fo
rE
xt
er
na
lQ
ua
lity
N
o
1
1
1
Sp
lit
sa
m
pl
e
pr
o
ce
du
re
;
co
m
pa
ris
on
w
ith
A
ss
ur
an
ce
fo
rL
ab
or
at
or
ie
s
in
H
ea
lth
Ca
re
a
st
an
da
rd
la
bo
ra
to
ry
m
et
ho
d
Fi
nl
an
d
La
bq
ua
lit
y
La
bq
ua
lit
y
Ye
s
1
2
2
H
un
ga
ry
Qu
ali
Co
nt
In
V
itr
o
D
ia
gn
os
tic
Qu
ali
ty
Co
nt
ro
l
Ye
s
2
6
12
N
on
pr
o
fit
Pu
bl
ic
U
til
ity
Lt
d.
N
et
he
rla
nd
s
EC
AT
Ex
te
rn
al
qu
al
ity
Co
nt
ro
lo
fd
ia
gn
os
tic
N
o
5
O
n
re
qu
es
t
N
A
QC
se
ts
o
ff
iv
e
ly
op
hi
liz
ed
pl
as
m
as
w
ith
A
ss
ay
s
an
d
Te
st
s
ce
rt
ifi
ed
IN
R
ta
rg
et
v
al
ue
s
ar
e
di
str
ib
ut
ed
to
th
e
pa
rti
ci
pa
nt
s
o
n
re
qu
es
t
N
et
he
rla
nd
s
FN
T
Fe
de
ra
tio
n
o
fN
et
he
rla
nd
s
Th
ro
m
bo
sis
Ye
s
2
5
10
H
om
e-
m
ad
e
co
n
tr
o
lm
at
er
ia
l(
fre
sh
fro
ze
n
se
rv
ic
es
po
ol
ed
pa
tie
nt
sa
m
pl
es
)
N
or
w
ay
N
O
K
LU
S
Th
e
N
or
w
eg
ia
n
Qu
ali
ty
Im
pr
o
v
em
en
t
o
f
Ye
s
2
2
4
Pr
im
ar
y
Ca
re
La
bo
ra
to
rie
s
Sw
itz
er
la
nd
CS
CQ
Th
e
Qu
ali
ty
Co
nt
ro
lC
en
te
rS
w
itz
er
la
nd
Ye
s
1
4
o
r
6
4
o
r
6
Sw
itz
er
la
nd
M
Q
A
ss
oc
ia
tio
n
o
fM
ed
ic
al
Qu
ali
ty
Co
nt
ro
l
Ye
s
1
4
4
Sp
lit
sa
m
pl
e
pr
o
ce
du
re
fo
rI
N
Ra
tio
u
se
rs
;
(N
of
or
IN
Ra
tio
)
co
m
pa
ris
on
w
ith
a
st
an
da
rd
la
bo
ra
to
ry
m
et
ho
d
U
K
U
K
N
EQ
AS
U
ni
te
d
K
in
gd
om
N
at
io
na
lE
xt
er
na
l
Ye
s
2
4
an
d
6
8
an
d
12
Qu
ali
ty
A
ss
es
sm
en
tS
ch
em
e
U
K
W
EQ
AS
W
el
sh
Ex
te
rn
al
Qu
ali
ty
A
ss
es
sm
en
t
Ye
s
1
6
6
H
om
e-
m
ad
e
co
n
tr
o
lm
at
er
ia
l(
art
ifi
cia
l
Sc
he
m
es
fro
ze
n
liq
ui
d
sa
m
pl
es
)
a
In
20
11
,t
hi
s
w
as
in
cr
ea
se
d
to
fo
ur
su
rv
ey
s
pe
ry
ea
r.
Brought to you by | Universitetsbiblioteket i Bergen (Universitetsbiblioteket i Bergen)
Authenticated | 172.16.1.226
Download Date | 2/10/12 3:16 PM
84 Stavelin et al.: External quality assessment of POCT INR in Europe
Article in press - uncorrected proof
a
bl
e
2
Th
e
to
ta
ln
u
m
be
ro
fp
ar
tic
ip
an
ts
an
d
ty
pe
o
fP
O
CT
IN
R
de
vi
ce
s
in
th
e
di
ffe
re
n
t
EQ
AS
.
Co
un
try
EQ
A
o
rg
an
iz
er
CC
a
,
CC
-S
CC
-X
S,
CC
-X
Sq
H
em
oc
hr
o
n
Pr
o
Ti
m
e
IN
Ra
tio
i-S
TA
T
Th
ro
m
bo
tra
ck
Si
m
pl
e
Si
m
on
Ti
lt-
tu
be
To
ta
l
U
K
U
K
N
EQ
AS
43
0
21
11
37
87
26
65
Sw
itz
er
la
nd
M
Q
10
55
11
52
37
20
22
64
Sw
itz
er
la
nd
CS
CQ
11
05
10
37
70
8
12
22
32
N
or
w
ay
N
O
K
LU
S
13
7
55
4
58
1
23
8
14
15
24
A
us
tri
a
O¨
QU
AS
TA
46
4
33
9
3
80
6
Cz
ec
h
R
ep
ub
lic
SE
K
K
20
24
0
10
27
0
Fi
nl
an
d
La
bq
ua
lit
y
3
15
0
2
15
5
U
K
W
EQ
AS
12
6
12
6
N
et
he
rla
nd
s
FN
T
43
64
4
11
1
N
et
he
rla
nd
s
EC
AT
20
55
75
D
en
m
ar
k
D
EK
S
0
H
un
ga
ry
Qu
ali
Co
nt
0
a
CC
,C
oa
gu
Ch
ek
.
results as target values. If a certain reagent lot is significantly
different to the mean or median, the results from these lots
are excluded before calculating the target value in the Nor-
wegian and the UKNEQAS scheme. The acceptability limits
used in the different EQAS vary from 15% to 30% (Table
4). In Norway and Switzerland (CSCQ), the uncertainty of
the target value is taken into account, meaning that the per-
centage acceptability limits will vary with the INR levels
(see example in Table 4).
Mandatory or voluntary participation
To receive reimbursement it is mandatory to participate in
the scheme in three of the nine countries (Table 4). In these
three countries, unacceptable results have consequences for
the participants. In Austria and Hungary, the participants will
not be awarded certification, but there are no financial or
legal consequences. In Switzerland, the laboratories are
obliged to participate in at least eight surveys in two years
and achieve 75% of the results within the acceptability limits,
or else reimbursement will be withheld for one year. In the
UK, where participation is voluntary, participants with per-
sistently unacceptable results are referred to the National
Quality Assurance Advisory Panel. If their performance does
not improve, it may be suggested that the center should stop
their service.
Supervision and education
In all countries, except in the Czech Republic and Finland,
participants are contacted, and guided, according to certain
criteria. In general, if a participant obtains an unacceptable
result, it will be contacted by the national EQA organizer,
mainly by letter, telephone or e-mail. The number of annual
participant meetings is none in the Czech Republic, the
Netherlands and Switzerland, one in Austria, Denmark, Fin-
land, Hungary and WEQAS, and at least one in Norway and
UKNEQAS.
Discussion
This study shows that nine countries in Europe offer an
EQAS for POCT INR, and that these schemes are organized
in various ways. Although we do not know the extent of the
use of POCT INR instruments in Europe, it is probable that
a lot of these users do not partake in an EQAS. However,
we cannot exclude the possibility that the POCT INR users
participate in other quality control systems that are not linked
to an EQA organizer.
An optimal EQAS should examine the trueness of the
instruments, and is characterized by the use of commutable,
stable and homogeneous control materials with the same
matrix as patient samples (20, 21). The target value should
be established by a reference method and the control samples
should be handled similar to patient samples. These optimal
conditions are, however, difficult to achieve in the EQAS for
POCT INR. A disadvantage with most of the present EQAS
is the use of lyophilized control material, which, due to
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able 4 Participation and acceptability limits in the different EQAS for POCT INR.
Country EQAS Participation Acceptability limits
Austria O¨ QUASTA Mandatory 30%a
Hungary QualiCont Mandatory 20%
Switzerland CSCQc and MQ Mandatory 15%
Czech Rep. SEKK Voluntary 20%
Denmark DEKS Voluntary 26%b
Finland Labquality Voluntary 15%
Netherlands ECAT and FNT Voluntary 15%
UK UKNEQAS Voluntary 15%
WEQAS Voluntary Excellent: F8%
Good: )8 and F16%
Unacceptable: )16%
Norway NOKLUSc Voluntary Good: F5%
Acceptable: )6 and F11%
Poor: )12%
aInformation for 2011 is 20%. bSplit sample procedure, deviation from a hospital method. cIncludes the uncertainty of the target value, this
means that the acceptability limit will differ in different INR levels. Example, NOKLUS: Calculation shown for level 2.5 INR: Target
values2.50 INR, target intervals2.45–2.55 INR, poor performance is -2.16 (2.45=0.88) or )2.86 (2.55=1.12) INR. The lower and
upper acceptable limits represent 14% of the target value ((2.50–2.16)/2.50s0.14 and (2.86–2.50)/2.50s0.14).
matrix effects (22), makes comparisons between different
brands of instruments difficult, and method specific target
values have to be used. In addition, since the procedure for
the control material is different from how native samples are
handled, artificial errors can be introduced. This is incon-
venient since the users of these instruments are often without
laboratory education. In spite of this, we consider partici-
pation in such schemes useful as they give valuable infor-
mation of the participant’s analytical quality compared to the
other users of the same method. Some EQA organizers have,
however, chosen not to offer this kind of scheme, as is the
case in Germany where they also have decided not to offer
EQAS for patient home testing due to these control material
matrix issues and the large number of patients (23).
Two EQA organizers employ a different control material
than the lyophilized samples (Table 3). WEQAS distributes
artificial liquid control samples where reconstitution and cal-
cium chloride activation is not required. This is an advan-
tage, but matrix effects are however still present. The most
native-like material is used by the FNT in the Netherlands.
A disadvantage using this native material is the short stability
(24), and all participants are therefore asked to analyze the
samples on the same day. Theoretically, this material could
be commutable and have common target values across meth-
ods groups, making it possible to compare different instru-
ment brands. Until now, however, method specific target
values have been used.
When no commercial control materials are available or
found acceptable for a POCT INR instrument, other types of
EQASs are conducted; in some countries, a split sample pro-
cedure using fresh patient samples is offered. This type of
quality control has been evaluated and found useful as an
alternative to the traditional EQAS (17), although it has been
opposed by others (25, 26). A different approach is devel-
oped in Austria and the Czech Republic where the INRatio
users are asked to report results from the on-board QC sys-
tem. Evaluation of the user’s reagent strips is not possible,
since one lot is distributed to all participants. This approach
makes it, however, possible to evaluate the interlaboratory
variation of one reagent lot, as well as the user’s competence.
The European concerted action on anticoagulation has
developed a set of five lyophilized control plasmas with cer-
tified INR target values for the CoaguChek instruments (27),
in order to examine the trueness of these instruments. These
controls are used by ECAT in the Netherlands (16). Since
the participant results are compared only with certified INR
values, it is not possible to compare one participant’s ana-
lytical quality with the other CoaguChek users. This
approach is, therefore, not an EQAS, but is more similar to
control systems where instruments are controlled with cer-
tified reference materials.
The frequency of the different EQAS varies from one to
six per year (Table 1). Guidelines recommend that a mini-
mum of four surveys should be conducted when the partic-
ipation is mandatory (28). The guideline is however based
on consensus and not on published evidence. A working
group in EQALM is currently dealing with optimum survey
frequency, investigating whether there is a relationship
between measurement quality and survey frequency. In the-
ory, similar to internal quality control, the control frequency
should be high when the prevalence of error is high in order
to increase the probability of early error detection (29, 30).
The acceptability limits used in the different EQAS varies
between countries (Table 4). In general, limits are narrower
in EQAS used for educational purposes compared to EQAS
where participation is mandatory (Table 4). Discrepancy in
acceptability limits means that a participant result can be
characterized as satisfactory in one country and unsatisfac-
tory in another. Ideally, the quality specifications should be
based on safe patient treatment or clinical outcome, the first
step in the quality goal hierarchy (31). The quality goals
established by EQA organizations are, however, mainly
based on a compromise between state of the art and bio-
logical variation (32).
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An important purpose of most European EQAS is to edu-
cate the participants. This is done by most of the organizers
through contact with the users and by including pre-
analytical and post-analytical schemes. This activity should
be extended and be an integrated part of all EQAS activity
(7). Post-analytical schemes have been conducted on a pro-
ject basis across European countries for different POCT anal-
ysis (33–35). For anticoagulation treatment a post-analytical
scheme is established in the Czech Republic (15), and recent-
ly a post-analytical survey for INR has been carried out in
fourteen European countries (personal communication).
The present study has investigated the availability and
organization of EQAS for POCT INR in Europe, but it has
not examined which EQA approach leads to best quality
improvement. An evidence-based conclusion recommending
one of these EQA approaches is therefore difficult to give.
Studies that examine the relationship between the type of
EQAS provided and the quality of the POCT INR instru-
ments in the hands of the users are needed.
In conclusion, this study demonstrates that there is a wide
variation in the way EQAS for POCT INR are performed in
Europe and that most European countries do not provide this
service. The disadvantages in most of the EQAS is the use
of lyophilized material that makes method specific target
values necessary and the probability that additional meas-
urement errors can be introduced by the pre-analytical han-
dling of the material. To obtain a material that can be handled
like patient samples and used across instrument platforms is
a major challenge. Even though EQAS for POCT INR faces
problems, they do provide important information and links
this with educational parts for the users. Participation in such
schemes is therefore considered useful, and users of POCT
INR instruments should be encouraged to participate in an
EQAS.
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